Table 2.

Retreatment criteria for patients requiring additional respective injections (Brolucizumab or Aflibercept) at each visit

Retreatment criteria

BCVA decrease by 0.10 from BCVA gained at 12-week review or last visit

OCT CMT increase by 75 µm from CMT attained at 12-week review

The appearance of new IRF spaces in central 1.5 mm, i.e. 750 µm from the foveal centre

The appearance of new SRF space in central 1.5 mm, i.e. 750 µm from the foveal centre

Increase in SRF height from the status achieved at 12-week review

BCVA Best-corrected visual acuity, OCT Optical coherence tomography, CMT Central macular thickness, IRF intraretinal fluid, SRF subretinal fluid